Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518999 | 0.89 | CXCR4 (0.60) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL1518990 | 0.83 | CXCR4 (0.61) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31252821 | 0.81 | CXCR4 (0.61) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL12836240 | 0.77 | IL23R (0.49) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29791638 | 0.77 | NPBWR1 (0.60) | CXCR4IL23RCCKBR | |
| SCHEMBL30008065 | 0.76 | CTSL (0.61) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30566367 | 0.75 | CXCR4 (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30808876 | 0.75 | CTSL (0.57) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL14155159 | 0.75 | CXCR4 (0.56) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL17327767 | 0.75 | CXCR4 (0.61) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8303973-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG | 2012-10-04 | — | — | US | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051444-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051483-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005018683-A2 | ANASTOMOTIC CONNECTOR DEVICES | ANGIOTECH INTERNATIONAL AG (CH) | 2005-03-03 | — | — | WO | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | CXCR4 2127/4885CTSL 2931/4885CTSS 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.